Therapeutics News and Research

RSS

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Researchers have tracked the genetic mutations that have occurred in the Ebola virus during the last four decades. Their findings, published in mBio, the online open-access journal of the American Society for Microbiology, identified changes in the current West African outbreak strain that could potentially interfere with experimental, sequence-based therapeutics.

21 Jan 2015

Researchers identify novel signaling pathway that triggers allergic asthma response

Researchers at the University of California, San Diego School of Medicine, with collaborators in Korea and Scotland, have identified a novel signaling pathway critical to the immune response of cells associated with the initiation of allergic asthma.

20 Jan 2015

Solvanix set up to commercialise novel antibody-stabilisation technology

The Garvan Institute of Medical Research announces the launch of spin-off company Solvanix Pty Ltd, set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies.

17 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced its first European symposium, detailing the use of Translational Platforms including Patient-Derived Xenograft (PDX) models in oncology drug discovery and development. The conference will be held on Wednesday 11th February, at the headquarters of One Nucleus in Cambridge, UK and will welcome experts from renowned pharmaceutical companies and prominent academics working in oncology.

15 Jan 2015

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers.

15 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis.

12 Jan 2015

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

From Precision NanoSystems Inc. 11 Jan 2015

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

This week 23andMe (a genetic testing company) and Genentech (medical research company of the Roche Group) agreed a collaboration to undertake whole genome sequencing for 3,000 patients with Parkinson’s disease. The genetic information will be collected by 23andMe and used by Genentech to identify new therapeutic targets for treating Parkinson’s disease.

9 Jan 2015

Nuo signs licensing and distribution agreement with Rohto for Aurix wound care system

Nuo Therapeutics, Inc., a pioneer in biodynamic therapies, today announced that it has signed an exclusive licensing and distribution agreement for the Aurix System with Rohto Pharmaceutical Co., Ltd., one of Japan’s leading pharmaceutical, health and wellness companies.

9 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.

8 Jan 2015

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.

8 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.

6 Jan 2015

New findings may lay groundwork of novel treatment for people with Huntington's disease

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder.

5 Jan 2015

Therapeutics News and Research

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Researchers identify novel signaling pathway that triggers allergic asthma response

Solvanix set up to commercialise novel antibody-stabilisation technology

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

Nuo signs licensing and distribution agreement with Rohto for Aurix wound care system

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Research findings could lead to new drug design for neurological diseases

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

EnGeneIC closes oversubscribed Series B financing

BrainStorm's phase 2a ALS study meets primary endpoint

New findings may lay groundwork of novel treatment for people with Huntington's disease

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News